KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation

Journal of Pathology

Volumn 234, Issue 2, 2014, Pages 239-252

  Ikenberg, Kristian ^a   Valtcheva, Nadejda ^a   Brandt, Simone ^a   Zhong, Qing ^a   Wong, Christine E ^a   Noske, Aurelia ^a   Rechsteiner, Markus ^a   Rueschoff, Jan H ^a   Caduff, Rosmarie ^a   Dellas, Athanassios ^b   Obermann, Ellen ^c   Fink, Daniel ^d   Fuchs, Thomas ^e   Krek, Wilhelm ^f   Moch, Holger ^a   Frew, Ian J ^g   Wild, Peter J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Ethikkommission Beider Basel   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

^e California Institute of Technology   (United States)

^f ETH ZURICH   (Switzerland)

^g UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Biomarker; EMT; Endometrial cancer; Importin; KPNA2; Snail

Indexed keywords

GELATINASE B; KARYOPHERIN ALPHA; KARYOPHERIN ALPHA 2; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; UVOMORULIN; BIOLOGICAL MARKER; KARYOPHERIN; KPNA2 PROTEIN, HUMAN; KPNA2 PROTEIN, MOUSE; NUCLEAR PROTEIN; TUMOR MARKER;

ADVANCED CANCER; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MODEL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MAJOR CLINICAL STUDY; MOUSE; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PRECANCER; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION; UTERUS; ANIMAL; EMT; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; KPNA2; METABOLISM; PATHOLOGY; PHYSIOLOGY; SNAIL; TUMOR CELL LINE;

BIOMARKER; EMT; ENDOMETRIAL CANCER; IMPORTIN; KPNA2; SNAIL;

ALPHA KARYOPHERINS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84907958839     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4390     Document Type: Article

References (49)

1. Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Saso S, Chatterjee J, Georgiou E, et al. Endometrial cancer. Br Med J 2011; 343: d3954.
3. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol 2007; 2: 57-85.
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
5. Humber C, Tierney J, Symonds P, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2005; CD003915.
6. Ishikawa M, Nakayama K, Rahman MT, et al. Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer. Oncology 2010; 79: 238-246.
7. Voss MA, Gordon N, Maloney S, et al. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 2011; 104: 1611-1618.
8. Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011; 104: 1418-1425.
9. Dahl E, Kristiansen G, Gottlob K, et al. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res 2006; 12: 3950-3960.
10. Dankof A, Fritzsche FR, Dahl E, et al. KPNA2 protein expression in invasive breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch 2007; 451: 877-881.
11. Gluz O, Wild P, Meiler R, et al. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer 2008; 123: 1433-1438.
12. Mortezavi A, Hermanns T, Seifert HH, et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2011; 17: 1111-1121.
13. Altan B, Yokobori T, Mochiki E, et al. Nuclear karyopherin-a2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer. Carcinogenesis 2013; 34: 2314-2321.
14. Grupp K, Habermann M, Sirma H, et al. High nuclear karyopherin a2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Mod Pathol 2014; 27: 96-106.
15. Jensen JB, Munksgaard PP, Sorensen CM, et al. High expression of karyopherin-a2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy. Eur Urol 2011; 59: 841-848.
16. Li C, Ji L, Ding ZY, et al. Overexpression of KPNA2 correlates with poor prognosis in patients with gastric adenocarcinoma. Tumour Biol 2013; 34: 1021-1026.
17. van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009; 124: 1829-1840.
18. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006; 98: 472-482.
19. Chook YM, Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol 2001; 11: 703-715.
20. Tseng SF, Chang CY, Wu KJ, et al. Importin KPNA2 is required for proper nuclear localization and multiple functions of NBS1. J Biol Chem 2005; 280: 39594-39600.
21. Teng SC, Wu KJ, Tseng SF, et al. Importin KPNA2, NBS1, DNA repair and tumorigenesis. J Mol Histol 2006; 37: 293-299.
22. Wang CI, Chien KY,Wang CL, et al. Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer. Mol Cell Proteomics 2012; 11: 1105-1122.
23. ZhengM, Tang L,Huang L, et al. Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 2010; 116: 884-891.
24. Wild PJ, Ikenberg K, Fuchs TJ, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med 2012; 4: 808-824.
25. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual (7th edn). Springer: New York, 2010; 403-418.
26. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009; 105: 109.
27. Graziano C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today 1998; 12: 1, 14-16.
28. Ke N, Wang X, Xu X, et al. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 2011; 740: 33-43.
29. Hall WJ, Wellner JA. Confidence bands for a survival curve from censored data. Biometrika 1980; 67: 133-143.
30. Therneau TM, Lumley T. survival: Survival analysis, including penalised likelihood. R package version 2.36-10 [Internet]. [Accessed 1 October 2011]. Available from: http://CRAN.Rproject. org/package=survival
31. Diez DM. OIsurv: Supplement to survival analysis tutorial. R package version 0.1. [Internet]. [Accessed 13 February 2012]. Available from: http://CRAN.R-project.org/package=OIsurv
32. Mimeault M, Batra SK. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann Oncol 2007; 18: 1605-1619.
33. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer 2002; 2: 442-454.
34. Morra L, Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch 2011; 459: 465-475.
35. Mhawech-Fauceglia P, Herrmann FR, Rai H, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2010; 133: 899-908.
36. Tong GX, Devaraj K, Hamele-Bena D, et al. Pax8: a marker for carcinoma of Müllerian origin in serous effusions. Diagn Cytopathol 2011; 39: 567-574.
37. Yemelyanova A, Ji H, Shih Ie M, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009; 33: 1504-1514.
38. Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009; 22: 522-529.
39. Konecny GE, Santos L,Winterhoff B, et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 2009; 100: 89-95.
40. Morrison C, ZanagnoloV, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24: 2376-2385.
41. Yoshitake K, Tanaka S,Mogushi K, et al. Importin-alpha1 as a novel prognostic target for hepatocellular carcinoma. Ann SurgOncol 2011; 18: 2093-2103.
42. Christiansen A, Dyrskjot L. The functional role of the novel biomarker karyopherin alpha 2 (KPNA2) in cancer. Cancer Lett 2013; 331: 18-23.
43. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Rev Drug Discov 2009; 8: 579-591.
44. Cutress ML, Whitaker HC, Mills IG, et al. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008; 121: 957-968.
45. Brys M, Semczuk A, Baranowski W, et al. Androgen receptor (AR) expression in normal and cancerous human endometrial tissues detected by RT-PCR and immunohistochemistry. Anticancer Res 2002; 22: 1025-1031.
46. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biol 2000; 2: 76-83.
47. Sekimoto T, Miyamoto Y, Arai S, et al. Importin alpha protein acts as a negative regulator for Snail protein nuclear import. J Biol Chem 2011; 286: 15126-15131.
48. Wang CI, Wang CL, Wang CW, et al. Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Cancer 2011; 128: 2364-2372.
49. Huang L,Wang HY, Li JD, et al. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a. Cell Death Dis 2013; 4: e745.